FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2209617680> ?p ?o ?g. }

• W2209617680 endingPage "84" @default.
• W2209617680 startingPage "71" @default.
• W2209617680 abstract "Standard systemic treatment of prostate cancer today is comprised of antihormonal and cytostatic agents. Vaccine therapy of prostate cancer is principally attractive because of the presence of tumor-associated antigens such as prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), prostate-specific membrane antigen (PSMA), and others. Most prostate cancer vaccine trials have demonstrated some activation of the immune system, limited clinical success, and few adverse effects. One strategy to overcome the problem of limited clinical success of vaccine therapies in prostate cancer could be strict patient selection. The clinical course of patients with prostate cancer (even in those with PSA relapse following surgery or radiotherapy with curative intention, or those with metastatic disease) can vary significantly. In patients with organ-confined prostate cancer, the most promising immunotherapeutic approach would be an adjuvant therapy following surgery or radiotherapy. Patients with PSA relapse following surgery or radiotherapy could also benefit from immunotherapy because tumor burden is usually low. However, most patients in prostate cancer vaccine trials had metastatic hormone-refractory prostate cancer (HRPC). High tumor burden correlates with immune escape phenomena. Nevertheless, 2 years ago, it was demonstrated, for the first time, that a tumor vaccine can prolong survival compared with placebo in patients with HRPC. This was demonstrated with the vaccine sipuleucel-T (APC-8015; Provenge®), a mixture of cells obtained from the patient’s peripheral blood by leukapheresis followed by density centrifugation and exposition. The Biologics License Application for this vaccine was denied by the US FDA in mid 2007, however, because the trial had failed to reach the primary endpoint (prolongation of time to tumor progression). Nevertheless, clinical trials with sipuleucel-T are ongoing, and the approach still looks promising. Another interesting approach is a vaccine made from whole tumor cells: GVAX®. This vaccine is presently being studied in phase III trials against, and in combination with, docetaxel. The results from these trials will become available in the near future. Besides the precise definition of the disease status of patients with prostate cancer, combinations of vaccine therapy with radiotherapy, chemotherapy, and/or hormonal therapy are approaches that look promising and deserve further investigation." @default.
• W2209617680 created "2016-06-24" @default.
• W2209617680 creator A5002400084 @default.
• W2209617680 creator A5004618159 @default.
• W2209617680 creator A5013257307 @default.
• W2209617680 creator A5040709504 @default.
• W2209617680 creator A5061907330 @default.
• W2209617680 date "2008-01-01" @default.
• W2209617680 modified "2023-10-16" @default.
• W2209617680 title "Prostate Cancer Vaccines" @default.
• W2209617680 cites W1566860764 @default.
• W2209617680 cites W1878925351 @default.
• W2209617680 cites W1964906479 @default.
• W2209617680 cites W1965734230 @default.
• W2209617680 cites W1965845785 @default.
• W2209617680 cites W1966141375 @default.
• W2209617680 cites W1969689519 @default.
• W2209617680 cites W1970759433 @default.
• W2209617680 cites W1980558129 @default.
• W2209617680 cites W1981326103 @default.
• W2209617680 cites W1988511213 @default.
• W2209617680 cites W1996382553 @default.
• W2209617680 cites W2000786003 @default.
• W2209617680 cites W2029643208 @default.
• W2209617680 cites W2032934787 @default.
• W2209617680 cites W2037988139 @default.
• W2209617680 cites W2039321642 @default.
• W2209617680 cites W2046507292 @default.
• W2209617680 cites W2052359153 @default.
• W2209617680 cites W2060790862 @default.
• W2209617680 cites W2068917085 @default.
• W2209617680 cites W2070613265 @default.
• W2209617680 cites W2074622312 @default.
• W2209617680 cites W2078066176 @default.
• W2209617680 cites W2078618230 @default.
• W2209617680 cites W2084377565 @default.
• W2209617680 cites W2086704878 @default.
• W2209617680 cites W2090890051 @default.
• W2209617680 cites W2094845525 @default.
• W2209617680 cites W2096435218 @default.
• W2209617680 cites W2098574945 @default.
• W2209617680 cites W2103090668 @default.
• W2209617680 cites W2112012653 @default.
• W2209617680 cites W2112053885 @default.
• W2209617680 cites W2113510389 @default.
• W2209617680 cites W2118436380 @default.
• W2209617680 cites W2120292596 @default.
• W2209617680 cites W2125416460 @default.
• W2209617680 cites W2130227816 @default.
• W2209617680 cites W2135172646 @default.
• W2209617680 cites W2142302700 @default.
• W2209617680 cites W2145803727 @default.
• W2209617680 cites W2149752186 @default.
• W2209617680 cites W2162052976 @default.
• W2209617680 cites W2162138091 @default.
• W2209617680 cites W2168219324 @default.
• W2209617680 cites W2261691410 @default.
• W2209617680 cites W2282988770 @default.
• W2209617680 cites W2423112668 @default.
• W2209617680 cites W32133297 @default.
• W2209617680 cites W4235084121 @default.
• W2209617680 doi "https://doi.org/10.2165/00063030-200822020-00001" @default.
• W2209617680 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18345705" @default.
• W2209617680 hasPublicationYear "2008" @default.
• W2209617680 type Work @default.
• W2209617680 sameAs 2209617680 @default.
• W2209617680 citedByCount "27" @default.
• W2209617680 countsByYear W22096176802012 @default.
• W2209617680 countsByYear W22096176802013 @default.
• W2209617680 countsByYear W22096176802014 @default.
• W2209617680 countsByYear W22096176802015 @default.
• W2209617680 countsByYear W22096176802016 @default.
• W2209617680 countsByYear W22096176802019 @default.
• W2209617680 countsByYear W22096176802020 @default.
• W2209617680 countsByYear W22096176802023 @default.
• W2209617680 crossrefType "journal-article" @default.
• W2209617680 hasAuthorship W2209617680A5002400084 @default.
• W2209617680 hasAuthorship W2209617680A5004618159 @default.
• W2209617680 hasAuthorship W2209617680A5013257307 @default.
• W2209617680 hasAuthorship W2209617680A5040709504 @default.
• W2209617680 hasAuthorship W2209617680A5061907330 @default.
• W2209617680 hasBestOaLocation W22096176801 @default.
• W2209617680 hasConcept C121608353 @default.
• W2209617680 hasConcept C126322002 @default.
• W2209617680 hasConcept C143998085 @default.
• W2209617680 hasConcept C203014093 @default.
• W2209617680 hasConcept C2776235491 @default.
• W2209617680 hasConcept C2776490512 @default.
• W2209617680 hasConcept C2776624504 @default.
• W2209617680 hasConcept C2777701055 @default.
• W2209617680 hasConcept C2778378633 @default.
• W2209617680 hasConcept C2779466945 @default.
• W2209617680 hasConcept C2780192828 @default.
• W2209617680 hasConcept C509974204 @default.
• W2209617680 hasConcept C535046627 @default.
• W2209617680 hasConcept C71924100 @default.
• W2209617680 hasConceptScore W2209617680C121608353 @default.
• W2209617680 hasConceptScore W2209617680C126322002 @default.

• next